News

U.S. IV Solutions Market to Reach $2.8 Billion by 2029, Driven by Outpatient Growth and Home-Based IV Therapy - New iData Research Report
PRNewswire/ - A new 2025 U.S. IV Solutions Market Report reveals that the IV Solutions market is projected to grow from ...
Medscape3d
Myeloma: OBI Rivals IV Isatuximab, Ups Patient Comfort
IRAKLIA, the first phase 3 multiple myeloma study to use an on-body injector, finds the same efficacy and pharmacokinetics in isatuximab, with many fewer infusion reactions.